SCHEMBL27329952

SCHEMBL27329952

O=C(O)CCc1ccc(O)c(CN(CCN(CC(=O)O)Cc2cc(CCC(=O)Oc3c(F)c(F)c(F)c(F)c3F)ccc2O)CC(=O)O)c1

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
FOLH1 Q04609 1/20 0.46
FFAR4 Q5NUL3 2/20 0.39
APP P05067 2/20 0.36
POLB P06746 2/20 0.35
CA1 P00915 8/20 0.34
CA2 P00918 8/20 0.34
CA4 P22748 2/20 0.34
THRA P10827 1/20 0.34
THRB P10828 1/20 0.34
PCNA P12004 1/20 0.34
MAPK1 P28482 1/20 0.34
HIF1A Q16665 1/20 0.34
CA12 O43570 1/20 0.33
CA9 Q16790 1/20 0.33
FFAR1 O14842 1/20 0.33
AKR1C3 P42330 1/20 0.33
AKR1C2 P52895 1/20 0.33
PPARD Q03181 1/20 0.33
PPARA Q07869 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29299539 0.95 FOLH1 (0.43) FOLH1FFAR4APPPOLBCA1
SCHEMBL24217610 0.95 FOLH1 (0.46) FOLH1FFAR4POLBCA1CA2
SCHEMBL22878071 0.89 FOLH1 (0.45) FOLH1FFAR4POLBCA1CA2
SCHEMBL1404313 0.85 FOLH1 (0.56) FOLH1FFAR4CA1CA2CA4
SCHEMBL27303602 0.82 FOLH1 (0.52) FOLH1FFAR4POLBCA1CA2
SCHEMBL25741233 0.82 FOLH1 (0.52) FOLH1FFAR4POLBCA1CA2
SCHEMBL25801389 0.80 FOLH1 (0.52) FOLH1FFAR4POLBCA1CA2
SCHEMBL22131080 0.80 FOLH1 (0.52) FOLH1PPARA
SCHEMBL25573716 0.79 FOLH1 (0.48) FOLH1POLBCA1CA2FFAR1
SCHEMBL18811743 0.79 FOLH1 (0.56) FOLH1FFAR4CA1CA2CA4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240226343-A1 NEUROPEPTIDE Y1 RECEPTOR (NPY1R) TARGETED THERAPEUTICS AND USES THEREOF RADIONETICS ONCOLOGY, INC. 2024-07-11 US disclosed
WO-2024129600-A1 GONADOTROPIN-RELEASING HORMONE RECEPTOR (GNRHR) TARGETED THERAPEUTICS AND USES THEREOF RADIONETICS ONCOLOGY, INC. (US) 2024-06-20 WO disclosed
WO-2024112612-A1 NEUROPEPTIDE Y1 RECEPTOR (NPY1R) TARGETED THERAPEUTICS AND USES THEREOF RADIONETICS ONCOLOGY, INC. (US) 2024-05-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240226343-A1 NEUROPEPTIDE Y1 RECEPTOR (NPY1R) TARGETED THERAPEUTICS AND USES THEREOF NPY1R, NPY2R, NPY4R FOLH1 335/4885FFAR4 417/4885APP 597/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.